Gramoz Brace

Learn More
The use of bevacizumab is increasingly reported in neuro-oncology. The most common schedule is 10 mg/kg every 2 weeks. We retrospectively investigated the efficacy of a 3-week schedule of 5 mg/kg bevacizumab in patients with recurrent glioblastomas. Fourteen patients (median age, 46 years) were included in the study. The median number of bevacizumab cycles(More)
INTRODUCTION To investigate the efficacy of platinum-based chemotherapy in patients with recurrent high-grade glioma (HGG) who had received previous alkylating line of chemotherapy. MATERIAL AND METHODS Case notes of patients who had received chemotherapy with carboplatin or cysplatin for recurrent HGG between June 2006 and July 2012 were reviewed.(More)
AIMS AND BACKGROUND Carboplatin (CBDCA) and bevacizumab (BEV) are active in glioblastoma (GBM) with different profiles of toxicity. To date, no study has compared the value of the addition of BEV to historical or traditional cytotoxic chemotherapy. We sought to determine the relative value of BEV in combination with CBDCA versus CBDCA alone in patients with(More)
Repeated sub-apnoeic doses of suxamethonium produce increased neuromuscular block in a hand muscle, measured by integrated electromyogram. The response to the initial dose varies widely between patients. More than 50% of patients showed evidence of non-depolarising block after one dose of suxamethonium. There was a variation between the response of the hand(More)
  • 1